Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Specific Anti-cd38 antibodies for treating human cancers

a technology of cd38 and specific antibodies, applied in the field of anti-cd38 antibodies, can solve the problems of antibody failure to induce apoptosis, and achieve the effect of reducing the charge of patients with chemotherapeutics

Inactive Publication Date: 2015-04-30
SANOFI SA
View PDF14 Cites 45 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about using anti-CD38 antibodies as a single agent to reduce the amount of chemotherapy a patient needs. This can help to make treatment more effective and reduce the side effects of chemotherapy.

Problems solved by technology

However, these antibodies fail to induce apoptosis when used as a single agent and incubated with CD38+ expressing cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Specific Anti-cd38 antibodies for treating human cancers

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0259]The inventors determined for the antibody hu38SB19 the suitable dose of administration and regimen in order to obtain a well-tolerated anti-cancer treatment that enables treating patients suffering from a CD38+ hematological malignancy, in particular, from multiple Myeloma, more particularly from relapsed and / or refractory multiple Myeloma.

[0260]The following example thus discloses the results of the Phase 1 clinical trials demonstrating safe therapeutic dose of this specific anti-CD38 antibody hu38SB19 for an efficient treatment of CD38+ hematological malignancy such as multiple myeloma in humans.

[0261]Patients

[0262]A total of 32 patients were treated in the study. 40.6% of the population were female; the mean age was 64.8 (±8.8). The Kornofsky status was greater than 60% in all patients.

[0263]The 32 patients included 3 patients with B-cell non-Hodgkins Lymphoma (NHL), 2 with chronic lymphocytic leukemia (CLL), and 27 with multiple myeloma (MM).

[0264]The 80.0% of the multiple...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg / kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

Description

RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application No. 61 / 898,309 filed Oct. 31, 2013, and European Patent Application No. EP14306220.6 filed Jul. 31, 2014, both of which are incorporated by reference into the present application in their entirety and for all purposes.SEQUENCE LISTING[0002]This application is accompanied by a sequence listing in a computer readable form that accurately reproduces the sequences described herein.FIELD OF THE INVENTION[0003]The present disclosure concerns treatment of disease using antibodies. More specifically, it relates to the use of anti-CD38 antibodies as a medicament or in the making of a medicament for treating cancers, such as multiple myeloma.BACKGROUND[0004]CD38 is a 45 kD type II transmembrane glycoprotein with a long C-terminal extracellular domain and a short N-terminal cytoplasmic domain. The CD38 protein is a bifunctional ectoenzyme that can catalyze the conversion of NAD+ into cyclic ADP-ri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28A61K39/395A61K31/573
CPCC07K16/2896A61K31/573C07K2317/76C07K2317/565A61K2039/505A61K39/3955A61K31/00A61K2039/545A61P35/00A61P35/02C07K2317/73C07K2317/732C07K2317/734C07K2317/75A61K2300/00
Inventor DESLANDES, ANTOINEGRZEGORZEWSKI, KRZYSZTOF J.OZOUX, MARIE-LAURETOMKINSON, BLAKE
Owner SANOFI SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com